Fig. 1From: A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol studyTrial scheme of the MOIO clinical trialBack to article page